*EXCLI Journal 2024;23:1183-1184 – ISSN 1611-2156*
*Received: May 13, 2024, accepted: September 04, 2024, published: September 05, 2024*

## Supplementary information to:

## Letter to the editor:

# PITFALLS IN THE USE OF SEX CHROMOSOME SEQUENCE MARKERS FOR INTERNAL QUALITY CONTROL OF NEXT-GENERATION SEQUENCING

Danielle Patchell, Stephen E. Langabeer*

Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland

* **Corrresponding author:** Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 W9RT, Ireland, Tel: +353 1 4162413, E-mail: slangabeer@stjames.ie

https://dx.doi.org/10.17179/excli2024-7387

*EXCLI Journal 2024;23:1183-1184 – ISSN 1611-2156*
*Received: May 13, 2024, accepted: September 04, 2024, published: September 05, 2024*

**Supplementary Table 1:** Cases with sex discrepancy detected by next-generation sequencing

| Case | Age | Reason for MPN request | Gender on request form | NGS genotyping | Explanation |
|---|---|---|---|---|---|
| 1 | 55 | post-HASCT erythrocytosis | F | XY | ALL post-HASCT; male donor |
| 2 | 56 | *CALR*$^{mut}$ MRD | F | XY | MDS/MPN post-HASCT; male donor |
| 3 | 58 | *CALR*$^{mut}$ MRD | F | XY | PMF post-HASCT; male donor |
| 4 | 60 | *CALR*$^{mut}$ MRD | F | XY | PMF post-HASCT; male donor |
| 5 | 32 | monocytosis, tear drop poikilocytes | M | XX | Ph+ ALL post-HASCT; female donor |
| 6 | 54 | post-HASCT erythrocytosis | M | XX | AML post-HASCT; female donor |
| 7 | 54 | *CALR*$^{mut}$ MRD | M | XX | PMF post-HASCT; female donor |
| 8 | 66 | *JAK2*$^{mut}$ MRD | M | XX | AML post-HASCT; female donor |
| 9 | 57 | *JAK2*$^{mut}$ MRD | M | XX | PPV-MF post-HASCT; female donor |
| 10 | 25 | erythrocytosis | F | XY | Male>female transgender reassignment |
| 11 | 47 | thrombocytosis | F | XY | Male>female transgender reassignment |
| 12 | 37 | erythrocytosis | F | XY | Male>female transgender reassignment |

MPN: myeloproliferative neoplasms; NGS: next-generation sequencing; HASCT: hematopoietic allogeneic stem cell transplant; ALL: acute lymphoblastic leukemia; MRD: measurable residual disease; MDS/MPN: myelodysplastic syndrome/myeloproliferative neoplasm; PMF: primary myelofibrosis; Ph+ ALL: Philadelphia chromosome-positive acute lymphoblastic leukemia; AML: acute myeloid leukemia; PPV-MF: post polycythemia vera-myelofibrosis